CervoMed: neflamapimod increases basal forebrain volume in DLB Phase 2b MRI analysis

CervoMed Inc.

At week 16, right BF volume increased 3.5% with neflamapimod vs -4.2% with placebo (p=0.028).
Right BF to DMN functional connectivity improved 46% during 32-week extension (p=0.014).
Improvement in functional connectivity correlated with CDR-SB reduction (p=0.027, r²=0.43).
Company plans to start Phase 3 trial in DLB later this year, subject to financing.
Data presented at 2026 AAN Annual Meeting by Amsterdam UMC; blinded analysis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.